Frenking JH, Zhou X, Wagner V, et al. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma. Journal for immunotherapy of cancer. 2024;12(10). doi:10.1136/jitc-2024-009220Google ScholarPubMedDOI

Pilcher WC, Yao L, Gonzalez-Kozlova E, et al. A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.05.15.593193PubMedDOIGoogle Scholar

Mo CC, Richardson E, Calabretta E, et al. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide. Blood reviews. 2024:101218. doi:10.1016/j.blre.2024.101218PubMedDOIGoogle Scholar

Mitsiades CS. Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics. Hematology/oncology clinics of North America. 2024. doi:10.1016/j.hoc.2023.12.016PubMedDOIGoogle Scholar

Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, et al. Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors. bioRxiv : the preprint server for biology. 2023. doi:10.1101/2023.08.01.551480Google ScholarPubMedDOI

Sklavenitis-Pistofidis R, Aranha MP, Redd RA, et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022;40(11):1358-1373.e8. doi:10.1016/j.ccell.2022.10.017PubMedDOIGoogle Scholar

Boiarsky R, Haradhvala NJ, Alberge JB, et al. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat Commun. 2022;13(1):7040. doi:10.1038/s41467-022-33944-zPubMedDOIGoogle Scholar

Bustoros M, Anand S, Sklavenitis-Pistofidis R, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13(1):3449. doi:10.1038/s41467-022-30694-wPubMedDOIGoogle Scholar

Went M, Sud A, Försti A, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018;9(1):3707. doi:10.1038/s41467-018-04989-wPubMedDOIGoogle Scholar

Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102(24):8567-72. doi:10.1073/pnas.0503221102PubMedDOIGoogle Scholar